Clinical Trial Update: Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rosuvastatin for effects on ventricular remodeling, lipids, and cytokines in heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• CRESTOR (Rosuvastatin)
• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure, Congestive | Phase 3 | Status: COMPLETED